152 related articles for article (PubMed ID: 35741225)
1. Quantitation of a Urinary Profile of Biomarkers in Gaucher Disease Type 1 Patients Using Tandem Mass Spectrometry.
Menkovic I; Boutin M; Alayoubi A; Curado F; Bauer P; Mercier FE; Auray-Blais C
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741225
[TBL] [Abstract][Full Text] [Related]
2. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.
Vernet Machado Bressan Wilke M; Iop GD; Faqueti L; Lemos da Silva LA; Kubaski F; Poswar FO; Michelin-Tirelli K; Randon D; Borelli WV; Giugliani R; Schwartz IVD
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474117
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of a plasma biomarker profile for the early detection of Gaucher disease type 1 patients.
Menkovic I; Boutin M; Alayoubi A; Curado F; Bauer P; Mercier FE; Rivard GÉ; Auray-Blais C
Bioanalysis; 2022 Feb; 14(4):223-240. PubMed ID: 35118875
[No Abstract] [Full Text] [Related]
4. Metabolomic Study Using Time-of-Flight Mass Spectrometry Reveals Novel Urinary Biomarkers for Gaucher Disease Type 1.
Menkovic I; Boutin M; Alayoubi A; Curado F; Bauer P; Mercier FE; Auray-Blais C
J Proteome Res; 2022 May; 21(5):1321-1329. PubMed ID: 35349295
[TBL] [Abstract][Full Text] [Related]
5. Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS/MS.
Tang C; Jia X; Tang F; Liu S; Jiang X; Zhao X; Sheng H; Peng M; Liu L; Huang Y
Clin Biochem; 2021 Jan; 87():79-84. PubMed ID: 33188770
[TBL] [Abstract][Full Text] [Related]
6. Multiplex Quantification of Plasma Biomarkers for Patients with Gaucher Disease Type 1.
Menkovic I; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc; 2023 Feb; 3(2):e696. PubMed ID: 36802221
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach.
Menkovic I; Boutin M; Alayoubi A; Mercier FE; Rivard GÉ; Auray-Blais C
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114153
[TBL] [Abstract][Full Text] [Related]
8. Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review.
Giuffrida G; Markovic U; Condorelli A; Calafiore V; Nicolosi D; Calagna M; Grasso S; Ragusa MTV; Gentile J; Napolitano M
Orphanet J Rare Dis; 2023 Feb; 18(1):27. PubMed ID: 36782327
[TBL] [Abstract][Full Text] [Related]
9. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A
Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512
[TBL] [Abstract][Full Text] [Related]
10. Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.
Revel-Vilk S; Fuller M; Zimran A
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998334
[TBL] [Abstract][Full Text] [Related]
11. Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study.
Curado F; Rösner S; Zielke S; Westphal G; Grittner U; Skrahina V; Alasel M; Malik AM; Beetz C; Böttcher T; Barel G; Sah AP; Dinur T; Anjum N; Ichraf Q; Kriouile Y; Hadipour Z; Hadipour F; Revel-Vilk S; Cozma C; Hartkamp J; Cheema H; Zimran A; Bauer P; Rolfs A;
Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685353
[TBL] [Abstract][Full Text] [Related]
12. An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan.
Ida H; Watanabe Y; Sagara R; Inoue Y; Fernandez J
Orphanet J Rare Dis; 2022 Nov; 17(1):401. PubMed ID: 36329499
[TBL] [Abstract][Full Text] [Related]
13. Combined analysis of plasma or serum glucosylsphingosine and globotriaosylsphingosine by UPLC-MS/MS.
Beasley J; McCaw P; Zhang H; Young SP; Stiles AR
Clin Chim Acta; 2020 Dec; 511():132-137. PubMed ID: 33058838
[TBL] [Abstract][Full Text] [Related]
14. Glucosylsphingosine Causes Hematological and Visceral Changes in Mice-Evidence for a Pathophysiological Role in Gaucher Disease.
Lukas J; Cozma C; Yang F; Kramp G; Meyer A; Neßlauer AM; Eichler S; Böttcher T; Witt M; Bräuer AU; Kropp P; Rolfs A
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29053611
[TBL] [Abstract][Full Text] [Related]
15. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
Hurvitz N; Dinur T; Becker-Cohen M; Cozma C; Hovakimyan M; Oppermann S; Demuth L; Rolfs A; Abramov A; Zimran A; Revel-Vilk S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234327
[TBL] [Abstract][Full Text] [Related]
16. Glucosylsphingosine (Lyso-Gb
Gayed MM; Jung SH; Huggins E; Rodriguez-Rassi E; DeArmey S; Kishnani PS; Stiles AR
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499264
[TBL] [Abstract][Full Text] [Related]
17. Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
Dinur T; Bauer P; Beetz C; Kramp G; Cozma C; Iurașcu MI; Becker-Cohen M; Istaiti M; Rolfs A; Zimran A; Revel-Vilk S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163551
[TBL] [Abstract][Full Text] [Related]
18. Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease.
Dinur T; Bauer P; Beetz C; Cozma C; Becker-Cohen M; Istaiti M; Rolfs A; Skrahina V; Zimran A; Revel-Vilk S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835356
[TBL] [Abstract][Full Text] [Related]
19. Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots.
Cozma C; Cullufi P; Kramp G; Hovakimyan M; Velmishi V; Gjikopulli A; Tomori S; Fischer S; Oppermann S; Grittner U; Bauer P; Beetz C; Rolfs A
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605119
[TBL] [Abstract][Full Text] [Related]
20. Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations.
Dinur T; Grittner U; Revel-Vilk S; Becker-Cohen M; Istaiti M; Cozma C; Rolfs A; Zimran A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
